Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

CIO October 28, 2011 Kim S. Nash	Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Pharmaceutical Executive November 1, 2013 Timothy Denman	Supply Chain: Scanning the Future The US and Europe are moving toward the enactment of new legislation that will change the way pharma products are handled and shipped throughout the supply chain.
Pharmaceutical Executive June 1, 2006 Jim Rittenburg	Toolkit: Safety in Numbers Mass serialization can protect the drug supply. But the next step forward will come from barcoding, not RFID.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
The Motley Fool January 19, 2010 Brian Orelli	Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious.
CIO October 28, 2011 Kim S. Nash	Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor.
IndustryWeek December 1, 2008 Jill Jusko	Focus on the Process Industries: Pharmaceuticals: Reworking the Pharma Supply Chain As multiple forces challenge the pharmaceutical industry, supply chains get a new look.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
Chemistry World May 7, 2013 Phillip Broadwith	Buy Viagra online - direct from the manufacturer Pharmaceutical giant Pfizer is cutting out the pharmacist middle-man by setting up a website for Viagra (sildenafil citrate) sales.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool September 7, 2007 Brian Orelli	Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications.
The Motley Fool February 9, 2010 Brian Orelli	Pfizer's Slippery Slope Discount cards for drugs help Pfizer track patients' use.
Pharmaceutical Executive July 3, 2007 George Koroneos	In Sync with California Pharmaceutical companies everywhere are preparing themselves for compliance with California's Electronic-Pedigree Mandates, which go into effect 18 months from now. When in place, an inspector will be able to receive, immediately, a record of any drug's chain of custody.
The Motley Fool August 10, 2007 Jack Uldrich	IBM Improves Its Pedigree Using RFID technology to track the supply chain of medications in order to stop the sale of counterfeit drugs could be big business in the not-to-distant future. IBM is ready to capture this business, with the launch of its ePedigree RFID system.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool December 6, 2011 Brian Orelli	Pfizer Faces Firing Line A panel of outside experts will help decide Inlyta's fate.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool April 24, 2009 Brian Orelli	Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters.
The Motley Fool January 15, 2008 Brian Orelli	Fewer Generics in Fido's Future TEVA considers selling its small animal-health business.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
Pharmaceutical Executive October 1, 2005	Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies.
The Motley Fool February 12, 2009 Brian Orelli	Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
The Motley Fool September 23, 2008 Brian Orelli	Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
CIO October 31, 2011 Maryfran Johnson	How Pfizer's CIO Led a Transformation of the Business Pharmaceutical giant Pfizer is using IT to drive new business.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
CIO February 15, 2004 Lafe Low	The 12th Annual CIO Enterprise Value Awards As always, competition was stiff for our winners. But this year we've added a twist-industry categories allowing companies to compete with business peers for this prestigious award-as well as a special new honor.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
InternetNews August 13, 2007 Larry Barrett	IBM's Tonic For Drug-Tracking Blues The latest version of IBM's WebSphere RFID Information Center software includes a new ePedigree feature that lets pharmaceutical companies create an electronic certificate of authenticity for every bottle, vial and package that wends its way through their supply chains.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.